

Updated survival analysis in patients with stage IIIB or receiving BLP25 liposome vaccine (L-BLP25): phase IIB trial

Journal of Cancer Research and Clinical Oncology

137, 1337-1342

DOI: [10.1007/s00432-011-1003-3](https://doi.org/10.1007/s00432-011-1003-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer. <i>Breast Care</i> , 2011, 6, 427-433.	0.8	4
2	Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. <i>Annals of Oncology</i> , 2012, 23, 1387-1393.	0.6	52
3	L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice. <i>Clinical Cancer Research</i> , 2012, 18, 2861-2871.	3.2	15
4	Emerging developments of chemoradiotherapy in stage III NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 591-598.	12.5	18
5	Particle-mediated delivery of cytokines for immunotherapy. <i>Immunotherapy</i> , 2012, 4, 425-441.	1.0	73
6	Toward an off-the-shelf vaccine for B-cell malignancies. <i>Blood</i> , 2012, 120, 1539-1540.	0.6	2
7	Immunotherapies for non-small-cell lung cancer and mesothelioma. <i>Lancet Oncology</i> , The, 2012, 13, e301-e310.	5.1	99
8	Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense. <i>Archives of Pharmacal Research</i> , 2012, 35, 1297-1316.	2.7	176
9	Liposomes and Other Nanoparticles as Cancer Vaccines and Immunotherapeutics. , 2012, , 135-178.		1
10	Targeting pattern recognition receptors in cancer immunotherapy. <i>Targeted Oncology</i> , 2012, 7, 29-54.	1.7	117
11	Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model. <i>Journal of Translational Medicine</i> , 2013, 11, 64.	1.8	24
12	Targeting the immune system for management of NSCLC: the revival?. <i>Current Respiratory Care Reports</i> , 2013, 2, 22-39.	0.6	1
13	Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 580-594.	1.3	12
14	Development of liposomal formulations: From concept to clinical investigations. <i>Asian Journal of Pharmaceutical Sciences</i> , 2013, 8, 81-87.	4.3	147
15	Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1021-1028.	0.8	144
17	Mucins and Cancer. , 2013, , .		2
18	Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2013, 42, 1119-1133.	3.1	14
19	Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer. <i>Expert Review of Vaccines</i> , 2013, 12, 263-270.	2.0	8

#	ARTICLE	IF	CITATIONS
20	Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. , 2013, 1, .		0
21	MUC1 immunotherapy is here to stay. Expert Opinion on Biological Therapy, 2013, 13, 35-49.	1.4	79
22	Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Annals of Oncology, 2013, 24, 2316-2324.	0.6	28
23	Immunotherapy in Lung Cancer: âœB7-Bombersâ€•and Other New Developments. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 810-821.	0.8	6
24	Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy. OncoImmunology, 2013, 2, e26285.	2.1	7
25	Locally Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 247-262.	1.0	19
26	What Lies Within: Novel Strategies in Immunotherapy for Nonâ€Small Cell Lung Cancer. Oncologist, 2013, 18, 1203-1213.	1.9	35
27	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270.	1.4	38
28	MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge. BioMed Research International, 2013, 2013, 1-10.	0.9	36
29	Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development. Journal of Visualized Experiments, 2013, , e50868.	0.2	6
31	Immunotherapy for Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2014, 77, 111.	0.7	19
32	Recent advances in immunotherapy for non-small-cell lung cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 352-357.	1.4	16
33	Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Review of Vaccines, 2014, 13, 87-116.	2.0	3
34	Tecemotide: An antigen-specific cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2014, 10, 3383-3393.	1.4	41
35	Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model. Cancer Immunology Research, 2014, 2, 581-589.	1.6	13
36	New Approaches in Immunotherapy for the Treatment of Lung Cancer. Current Topics in Microbiology and Immunology, 2014, 405, 1-31.	0.7	9
37	Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy, 2014, 6, 1221-1235.	1.0	44
38	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncology, 2014, 10, 79-90.	1.1	23

#	ARTICLE	IF	CITATIONS
39	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1495-1513.	1.1	8
40	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 59-68.	5.1	446
41	Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 161-174.	2.0	23
43	Therapeutic vaccination for non-small-cell lung cancer: a meta-analysis. <i>Medical Oncology</i> , 2014, 31, 928.	1.2	3
44	Liposomes as vaccine delivery systems: a review of the recent advances. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 159-182.	2.7	400
45	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1173-1187.	1.1	25
46	New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice. <i>Clinical Cancer Research</i> , 2014, 20, 1067-1073.	3.2	52
47	The State of the Art in Nonâ€“Small Cell Lung Cancer Immunotherapy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2014, 26, 26-35.	0.4	11
48	Immunotherapy in non-small-cell lung cancer: a good start?. <i>Lancet Oncology</i> , The, 2014, 15, 5-6.	5.1	3
49	Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 685-694.	0.4	44
50	Systemic and Targeted Therapies for Early-Stage Lung Cancer. <i>Cancer Control</i> , 2014, 21, 21-31.	0.7	22
51	Clinical Trials Integrating Immunotherapy and Radiation for Nonâ€“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1685-1693.	0.5	62
52	Nonâ€“Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 974-984.	0.5	127
53	Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. <i>BMJ Open</i> , 2015, 5, e006321-e006321.	0.8	6
54	A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma. <i>Journal of Translational Medicine</i> , 2015, 13, 166.	1.8	9
55	Emerging Immunotherapies in the Treatment of Nonâ€“small Cell Lung Cancer (NSCLC). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 422-430.	0.6	64
56	Vaccine immunotherapy in lung cancer: Clinical experience and future directions. , 2015, 153, 1-9.		34
57	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 689-702.	1.1	10

#	ARTICLE	IF	CITATIONS
58	Altered intracellular region of <scp>MUC</scp>1 and disrupted correlation of polarity-related molecules in breast cancer subtypes. <i>Cancer Science</i> , 2015, 106, 307-314.	1.7	8
59	Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour. <i>Current Topics in Microbiology and Immunology</i> , 2015, 405, 79-97.	0.7	8
61	Dietary Intake and Serum Level of Carotenoids in Lung Cancer Patients: A Case-Control Study. <i>Nutrition and Cancer</i> , 2015, 67, 893-898.	0.9	12
62	Engineered materials for cancer immunotherapy. <i>Nano Today</i> , 2015, 10, 511-531.	6.2	96
63	Immunotherapy for lung cancer: for whom the bell tolls?. <i>Tumor Biology</i> , 2015, 36, 1411-1422.	0.8	17
64	Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. <i>Annals of Oncology</i> , 2015, 26, 1134-1142.	0.6	83
65	Vaccine therapy in NSCLC: a review. <i>Lung Cancer Management</i> , 2015, 4, 31-41.	1.5	1
66	Biophysical, biopharmaceutical and toxicological significance of biomedical nanoparticles. <i>RSC Advances</i> , 2015, 5, 47830-47859.	1.7	44
67	Why has active immunotherapy not worked in lung cancer?. <i>Annals of Oncology</i> , 2015, 26, 2213-2220.	0.6	35
68	Update on Mucin-1 immunotherapy in cancer: a clinical perspective. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1773-1787.	1.4	36
69	Lung cancer: Biology and treatment options. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 189-210.	3.3	526
70	The future of immunotherapy in the treatment of lung cancer. <i>Lung Cancer Management</i> , 2015, 4, 57-73.	1.5	2
71	Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer. <i>Annals of Oncology</i> , 2015, 26, 1838-1845.	0.6	15
72	Racotumomab- α alum vaccine for the treatment of non-small-cell lung cancer. <i>Expert Review of Vaccines</i> , 2015, 14, 9-20.	2.0	8
73	Nanoformulations. , 2016, , 307-330.		0
74	A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers. <i>Theranostics</i> , 2016, 6, 666-678.	4.6	11
75	Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application. , 2016, , 813-869.		5
76	Dendritic cell-based vaccine for pancreatic cancer in Japan. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 133.	0.6	22

#	ARTICLE	IF	CITATIONS
77	Non-small cell lung cancer: current treatment and future advances. <i>Translational Lung Cancer Research</i> , 2016, 5, 288-300.	1.3	1,256
78	The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 286.	1.8	7
79	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. <i>Annals of Translational Medicine</i> , 2016, 4, 268-268.	0.7	16
80	MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. <i>Oncolmmunology</i> , 2016, 5, e1117738.	2.1	53
81	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	1.0	29
82	Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3204-3212.	0.8	46
83	The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2016, 6, 32020.	1.6	18
84	Immune Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 59-90.	0.8	1
85	Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo. <i>Journal of Controlled Release</i> , 2016, 225, 205-216.	4.8	52
86	Immunotherapy of Cancer. , 2016, , .		3
87	Dendritic Cell-Based Vaccine for Cancer. , 2016, , 197-220.		0
88	Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 105, 23-30.	0.9	30
89	A comprehensive review of immunotherapies in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 292-303.	2.0	55
90	The swinging pendulum of cancer immunotherapy personalization. <i>Personalized Medicine</i> , 2017, 14, 259-270.	0.8	3
91	Immunotherapy in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 131-141.	0.9	31
92	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. <i>ESMO Open</i> , 2017, 2, e000200.	2.0	31
94	Immunotherapy Comes of Age in Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 13-22.	1.1	68
96	Immunotherapy for thoracic malignancies. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 34, 54-64.	0.2	0

#	ARTICLE	IF	CITATIONS
97	Vaccine and immune cell therapy in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1602-S1614.	0.6	30
98	Combining immunotherapy and radiotherapy in lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1447-S1460.	0.6	54
99	Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme. <i>Frontiers in Oncology</i> , 2018, 8, 521.	1.3	13
100	Cancer Vaccines. , 2018, , 161-184.e6.		2
101	Peptide Delivery Systems for Cancer Vaccines. <i>Advanced Therapeutics</i> , 2018, 1, 1800060.	1.6	30
102	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 931-940.	0.9	10
103	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. <i>Mayo Clinic Proceedings</i> , 2018, 93, 917-936.	1.4	4
104	MUC1 and Cancer Immunotherapy. , 2018, , 225-240.		5
105	MUC1 in Cancer Immunotherapy â€” New Hope or Phantom Menace?. <i>Biochemistry (Moscow)</i> , 2019, 84, 773-781.	0.7	12
106	Physical and chemical profiles of nanoparticles for lymphatic targeting. <i>Advanced Drug Delivery Reviews</i> , 2019, 151-152, 72-93.	6.6	79
107	Cationic synthetic long peptides-loaded nanogels: An efficient therapeutic vaccine formulation for induction of T-cell responses. <i>Journal of Controlled Release</i> , 2019, 315, 114-125.	4.8	31
108	Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy. , 2019, 7, 238.		33
109	Particulate carrier systems as adjuvants for cancer vaccines. <i>Biomaterials Science</i> , 2019, 7, 4873-4887.	2.6	17
110	Immunomodulatory Nanosystems. <i>Advanced Science</i> , 2019, 6, 1900101.	5.6	255
111	Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. <i>Vaccine</i> , 2019, 37, 2090-2098.	1.7	7
112	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190024.	3.0	47
113	Therapeutic vaccines for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2019, , .	1.5	6
115	Peptide and Protein Vaccines for Cancer. , 2019, , 101-116.		4

#	ARTICLE	IF	CITATIONS
116	Candidate Cancers for Vaccination. , 2019, , 145-152.		2
117	Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines. , 2019, , 171-176.		1
118	Selective outcome reporting is present in randomized controlled trials in lung cancer immunotherapies. Journal of Clinical Epidemiology, 2019, 106, 145-146.	2.4	8
119	Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles. Current Topics in Microbiology and Immunology, 2020, 433, 29-76.	0.7	12
120	A review on development of MUC1-based cancer vaccine. Biomedicine and Pharmacotherapy, 2020, 132, 110888.	2.5	73
121	Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 162.	3.5	10
122	Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy. Chemical Engineering Journal, 2020, 399, 125854.	6.6	29
123	Immune cell engineering: opportunities in lung cancer therapeutics. Drug Delivery and Translational Research, 2020, 10, 1203-1227.	3.0	3
124	Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines. Cancers, 2020, 12, 1049.	1.7	51
125	Cancer Immunology and the Evolution of Immunotherapy. , 2021, , 3-29.		1
126	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Frontiers in Immunology, 2020, 11, 615240.	2.2	59
127	Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. Thoracic Cancer, 2021, 12, 2732-2739.	0.8	4
128	Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. Critical Reviews in Oncology/Hematology, 2021, 164, 103417.	2.0	18
129	Nanovaccine: an emerging strategy. Expert Review of Vaccines, 2021, 20, 1273-1290.	2.0	50
130	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2
131	Overview of Lung Cancer Immunotherapy. Cancer Journal (Sudbury, Mass), 2020, 26, 473-484.	1.0	6
132	Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer. Cancer Control, 2013, 20, 22-31.	0.7	53
133	Strategies for developing and optimizing cancer vaccines. F1000Research, 2019, 8, 654.	0.8	43

#	ARTICLE	IF	CITATIONS
134	Cancer Associated Aberrant Protein O-Glycosylation Can Modify Antigen Processing and Immune Response. PLoS ONE, 2012, 7, e50139.	1.1	54
135	Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. Current Cancer Drug Targets, 2019, 19, 199-209.	0.8	1
136	Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects. World Journal of Gastroenterology, 2015, 21, 8052.	1.4	17
137	L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. Journal of Thoracic Disease, 2014, 6, 1513-20.	0.6	17
138	Immunotherapy in lung cancer. Translational Lung Cancer Research, 2014, 3, 2-14.	1.3	53
139	Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Translational Lung Cancer Research, 2014, 3, 34-45.	1.3	22
140	Lung cancer vaccines: current status and future prospects. Translational Lung Cancer Research, 2014, 3, 46-52.	1.3	14
141	Immunotherapy in lung cancer. Translational Lung Cancer Research, 2014, 3, 53-63.	1.3	50
142	Cancer stem cells and immunoresistance: clinical implications and solutions. Translational Lung Cancer Research, 2015, 4, 689-703.	1.3	91
143	Targeted immunotherapy for non-small cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 39.	0.9	7
144	Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines. , 0, , .		4
145	Advances in Lung Cancer and Treatment Research. Journal of Cancer Therapy, 2013, 04, 36-43.	0.1	1
146	Cancer Vaccines and the Potential Benefit of Combination with Standard Cancer Therapies. , 2013, , 347-359.		0
147	Non-small Cell Lung Cancer, NSCLC. , 2014, , 193-201.		2
148	Cancer Vaccines. , 2016, , 295-333.		0
149	Lipid in Chips: A Brief Review of Liposomes Formation by Microfluidics. International Journal of Nanomedicine, 2021, Volume 16, 7391-7416.	3.3	41
150	Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccines. Iranian Journal of Basic Medical Sciences, 2014, 17, 772-8.	1.0	1
151	Immunotherapy for lung cancer: advances and prospects. American Journal of Clinical and Experimental Immunology, 2016, 5, 1-20.	0.2	28

#	ARTICLE	IF	CITATIONS
156	Immunization with short peptide particles reveals a functional CD8 ⁺ T-cell neoepitope in a murine renal carcinoma model. , 2021, 9, e003101.		7
157	Metal-based nano-vaccines for cancer immunotherapy. Coordination Chemistry Reviews, 2022, 455, 214345.	9.5	27
159	Design of a new multi-epitope peptide vaccine for non-small cell Lung cancer via vaccinology methods: an study.. Molecular Biology Research Communications, 2022, 11, 55-66.	0.2	1
163	Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines, 2022, 10, 740.	2.1	4
164	Liposomal formulations for lung cancer treatment in the last two decades: a systematic review. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	2
165	Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine. Frontiers in Nanotechnology, 0, 4, .	2.4	2
166	Understanding the Molecular Kinetics in NSCLC Through Computational Method. , 2022, , 129-163.		0
167	Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. Advanced Science, 2022, 9, .	5.6	20
168	Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. Frontiers in Immunology, 0, 13, .	2.2	5
169	Recent Advances in Cancer Immunotherapy Delivery Modalities. Pharmaceutics, 2023, 15, 504.	2.0	5
170	Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer, 2023, 22, .	7.9	104
171	Nanomedicine in Lung Cancer Immunotherapy. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	12
174	Future Perspectives of Cancer Immunotherapy for the Treatment of Lung Cancer. , 2024, , 373-389.		0